Skip to content
ClinCalc Pro
Menu
NMDA Receptor Antagonist — Opioid-Sparing Analgesic

Ketamine (Sub-anaesthetic — Orthopaedic Pain)

Brand names: Ketalar

Sub-anaesthetic (low-dose) ketamine is an NMDA-receptor antagonist used as an analgesic adjunct for acute, severe or opioid-refractory orthopaedic and trauma pain, often to reduce opioid requirements.

Dosing — not shown for this use

The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.

The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Ketamine.

Clinical monograph

How it works

It non-competitively antagonises NMDA glutamate receptors, attenuating central pain sensitisation and wind-up; at sub-anaesthetic doses it provides analgesia without full anaesthesia.

Prescribing in practice

  • Administer in a setting with appropriate monitoring because of psychotomimetic effects (dissociation, hallucinations), and use cautiously in uncontrolled hypertension, raised intracranial pressure and ischaemic heart disease as it raises blood pressure and heart rate.
  • It can cause emergence reactions, nausea and increased secretions; caution in those with a history of psychosis.
  • Effects may be additive with other CNS depressants and opioids; reserve initiation and titration to clinicians experienced in its use.

Monitoring

Monitor blood pressure, heart rate, conscious level and for dissociative or psychotomimetic effects during administration.

Counselling the patient

  • You may feel detached, dreamy or experience odd sensations while it is given.
  • Tell staff if you feel distressed, nauseated or unwell during treatment.
  • It is used to improve pain control and reduce reliance on strong opioids.

Evidence & guidelines

Guidance on acute pain supports low-dose ketamine as an opioid-sparing analgesic adjunct in severe or refractory pain within monitored settings.

Reference: NICE NG124 (Hip Fracture); BOAST Open Fracture Guidelines; MHRA Ketamine Scheduling 2014; SPC Ketalar; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.